Roche is more than doubling its total commitment to a future facility for its Genentech unit to approximately $2 billion. The plant, being built in Holly Springs, North Carolina, will be used to crank out next-generation drugs for metabolic conditions like obesity, Roche has said.
Roche scales Genentech’s North Carolina site to $2B in major obesity market play
Latest from Blog
Supreme Court rules in weedkiller cancer case
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. It’s Pride Weekend here in New York City, so a big gay hello to
Jails are the frontline in fielding dangerous new type of drug withdrawal
When Lillian was booked into a rural Pennsylvania jail, she couldn’t stop vomiting. As she showered and changed into her jail uniform, “brain zaps” kept destabilizing her. “The corrections officer watching me
What is pulmonary hypertension and why would a new GLP-1 help?
On Tuesday STAT reported on a mystery patient with obesity, sleep apnea, and pulmonary hypertension who’d received an obesity drug not yet approved by federal drug regulators. The identity of the 79-year-old
Child malnutrition in Nepal has reached ‘alarming’ levels since aid cuts, survey finds
Fears hard-won gains in reducing child mortality over 20 years are at risk after end of USAID funding for nutrition programmes Post Views: 2
Most bees are solitary and don’t live in hives. Climate change risks them starving
Scientists don’t know enough about the food habits of less social bees. Here’s why that urgently needs to change. Post Views: 2